Questions discussed in this category
At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...
In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...
Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...
When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...
2016820523203481887317941179401768813393
Papers discussed in this category
N Engl J Med, 2021 Dec 11
Blood advances, 2023 Sep 26
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Neurooncol Adv, 2023 Jan-Dec